David M. Mott - 17 May 2022 Form 4 Insider Report for Epizyme, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 17 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2022, 16:26:18 UTC
Prior SEC filing: 01 Apr 2022
Next SEC filing: 03 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/John Weidenbruch, attorney-in-fact

Key filing fact

David M. Mott filed Form 4 for Epizyme, Inc. on 19 May 2022.

Key facts

This page summarizes David M. Mott's Form 4 filing for Epizyme, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 May 2022, 16:26.

Change

Previous filing in this sequence was filed on 01 Apr 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EPZM transaction

Common Stock, par value $0.0001

Award

Transaction value: $0
Shares: +8,994
Change %: +4.5%
Price: $0.000000
Shares after: 208,332
Date: 17 May 2022
Ownership: Direct
Footnotes: F1

EPZM holding

Common Stock, par value $0.0001

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 106,959
Date: 17 May 2022
Ownership: See Note
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EPZM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +41,006
Change %
Price: $0.000000
Shares after: 41,006
Date: 17 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 41,006
Exercise price: $0.5600
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Consists of shares of Common Stock issuable under 8,994 restricted stock units ("RSUs") granted on May 17, 2022, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. Each RSU represents the right to receive one share of Common Stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full.

Footnote F2

The shares are directly held by the David Mott Declaration of Trust dated May 31, 2001 as amended (the "Mott Trust"). The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the Mott Trust shares in which the Reporting Person has no pecuniary interest.

Footnote F3

This option was granted on May 17, 2022 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full.